Security profile of direct anticoagulants. Preferred use in atrial fibrillation
Clin Investig Arterioscler. 2019 Nov-Dec;31(6):263-270.
doi: 10.1016/j.arteri.2019.03.002.
Epub 2019 Jun 15.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio Cardiología, Hospital Universitario La Paz, CIBER-CV, Madrid, España.
- 2 Servicio Neurología, Hospital Universitario La Paz, Madrid, España.
- 3 Servicio de Medicina Interna, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, España.
- 4 Servicio de Hematología, Clínica Universidad de Navarra, CIBER-CV, Pamplona, España. Electronic address: japaramo@unav.es.
Abstract
A multidisciplinary panel of cardiologists, neurologists, internal medicine and specialists in hemostasis and thrombosis has elaborated this document showing recent scientific evidences supporting a better profile of direct oral anticoagulants (DOACs) versus vitaminK antagonists (VKA), as well as the indications of specific antidotes and hemostatic agents to reverse the anticoagulant effects of DOACs. The analysis reinforces the best profile of DOACs and its special benefit in patients with basal high hemorrhagic risk.
Keywords:
Anticoagulantes orales de acción directa; Antidotes; Antídotos; Direct oral anticoagulants; Gastrointestinal bleeding; Hemorragia gastrointestinal; Hemorragia intracraneal; Intracranial hemorrhage.
Copyright © 2019 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Anticoagulants / adverse effects
-
Anticoagulants / therapeutic use
-
Antidotes / therapeutic use
-
Antithrombins / adverse effects*
-
Antithrombins / therapeutic use
-
Atrial Fibrillation / complications*
-
Cerebral Hemorrhage / chemically induced
-
Cerebral Hemorrhage / prevention & control
-
Cerebral Hemorrhage / therapy
-
Dabigatran / adverse effects
-
Dabigatran / therapeutic use
-
Gastrointestinal Hemorrhage / chemically induced
-
Gastrointestinal Hemorrhage / therapy
-
Hemorrhage / chemically induced
-
Hemorrhage / etiology
-
Hemorrhage / prevention & control*
-
Hemorrhage / therapy
-
Humans
-
Practice Guidelines as Topic
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Pyridines / adverse effects
-
Pyridines / therapeutic use
-
Pyridones / adverse effects
-
Pyridones / therapeutic use
-
Risk Factors
-
Rivaroxaban / adverse effects
-
Rivaroxaban / therapeutic use
-
Stroke / etiology
-
Stroke / prevention & control*
-
Thiazoles / adverse effects
-
Thiazoles / therapeutic use
Substances
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants
-
Antidotes
-
Antithrombins
-
Pyrazoles
-
Pyridines
-
Pyridones
-
Thiazoles
-
apixaban
-
idarucizumab
-
Rivaroxaban
-
Dabigatran
-
edoxaban